EUVIMEDSkopri EUVIMED
Crossref

The implications of losing treatment options: Why lasmiditan's discontinuation matters

Juliana H VanderPluym iD

Headache: The Journal of Head and Face Pain · 2026-02 · 66 (2) · 554-555

DOI: 10.1111/head.70041 ↗

At a glance

Journal article in Headache: The Journal of Head and Face Pain, published online on 2026-01-05. Written by Juliana H VanderPluym. Institution: Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA. Cited 3 times so far (Crossref); 7 references.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Ebda abstract disponibbli.

Subjects

Author keywords

discontinuationlasmiditanmigraine

Authors and institutions

  • Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA.

ORCID profiles: Juliana H VanderPluym

Cite

APA

VanderPluym, J. H. (2026). The implications of losing treatment options: Why lasmiditan's discontinuation matters. Headache: The Journal of Head and Face Pain, 66(2), 554-555. https://doi.org/10.1111/head.70041

Vancouver

VanderPluym JH. The implications of losing treatment options: Why lasmiditan's discontinuation matters. Headache: The Journal of Head and Face Pain. 2026;66(2):554-555. doi:10.1111/head.70041

BibTeX
@article{VanderPluym2026,
  author = {VanderPluym, Juliana H},
  title = {The implications of losing treatment options: Why lasmiditan's discontinuation matters},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2026},
  volume = {66},
  number = {2},
  pages = {554--555},
  doi = {10.1111/head.70041}
}
Start for free →